Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most muscle-related side effect content (e.g., myalgia, muscle weakness, rare serious muscle injury/rhabdomyolysis) is directionally supported by the label excerpt, but several claims include specific experiential timing/behavioral descriptions (e.g., tightness with yoga, noticeable during normal activity, posed-related noticing) and an unsubstantiated framing about 'key connection' between statins and flexibility/range-of-motion, which are not supported by the provided label text.
Category Scores
Accurate Statements
Possible muscle-related side effects of Lipitor include muscle aches, soreness, or pain (myalgia).
Section 6.1 lists myalgia as a common adverse reaction leading to discontinuation (myalgia 0.7%).
Some muscle problems linked to statins are rare but serious.
Section 5.1 describes rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria.
Severe muscle injury can occur in rare cases related to statins including Lipitor.
Section 5.1: rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria reported with LIPITOR.
If a person notices new muscle pain, stiffness, or weakness after starting Lipitor (or after dose changes), they should contact their clinician.
Section 5.1 supports that atorvastatin can occasionally cause myopathy and rare rhabdomyolysis; however the excerpt does not explicitly include patient advice language. This is assessed as only partially supported overall.
If Lipitor muscle symptoms occur after starting Lipitor or after dose changes, Lipitor becomes a more likely contributor.
The label excerpt supports that myopathy/rhabdomyolysis risk is influenced by treatment context (e.g., risk increased with higher doses and interacting drugs) in Section 5.1, but it does not explicitly state the 'after starting/dose changes becomes more likely' framing.
Unsupported Statements
If Lipitor causes muscle symptoms, those symptoms can make stretches and yoga poses feel tighter or harder.
No label excerpt mentions flexibility changes, stretching, yoga, or effects on range of motion.
Muscle-related side effects are the key connection between statins and flexibility changes, rather than a direct effect on joints or range of motion.
Label excerpt does not discuss flexibility/range-of-motion changes or whether joints are directly affected.
Possible muscle-related side effects of Lipitor include muscle weakness.
The provided label excerpt does not list muscle weakness as a specific adverse reaction. Section 5.1 discusses myopathy/rhabdomyolysis risk but the excerpt does not explicitly name weakness.
Possible muscle-related side effects of Lipitor include muscle cramps or stiffness.
The provided label excerpt does not explicitly list cramps or stiffness as muscle adverse reactions.
Muscle-related side effects of Lipitor can show up during normal activity.
No label excerpt states timing relative to activities of daily living or normal activity.
Muscle-related side effects of Lipitor may be most noticeable when performing deeper stretches, holding positions, or transitioning into poses requiring strength and control.
No label excerpt supports activity-specific noticing patterns or stretch/pose scenarios.
Severe muscle pain or tenderness can be a red flag for Lipitor muscle problems.
The label excerpt does not explicitly describe 'red flags' or symptoms such as tenderness as actionable warnings.
Noticeable weakness can be a red flag for Lipitor muscle problems.
The label excerpt does not explicitly describe weakness as a 'red flag' symptom.
Dark or cola-colored urine can be a red flag for Lipitor muscle problems.
The label excerpt mentions myoglobinuria in rhabdomyolysis but does not describe 'dark/cola-colored urine' as a red-flag for patients.
Fever or feeling very unwell can be a red flag for Lipitor muscle problems.
The label excerpt does not identify fever or feeling unwell as red-flag symptoms for muscle problems.
Clinicians may consider lab testing for statin-related muscle symptoms, often including muscle enzymes like CK.
The provided label excerpt does not mention CK or muscle-enzyme testing for myopathy.
Clinicians may adjust the dose or switch to a different cholesterol medication if symptoms fit statin-related effects.
While Section 5.1 discusses risk increases and Section 5.2 discusses dose reduction/withdrawal for persistent transaminase elevations, the excerpt does not provide guidance to adjust dose or switch therapy specifically for muscle symptoms.
One should not stop Lipitor on their own.
The provided label excerpt does not explicitly state patient instructions regarding stopping on their own.
Contradictions
Important Omissions
Label-specific contraindications and explicit warnings are not discussed in the claims list (e.g., active liver disease, pregnancy/fetal harm, nursing mothers).
Importance:
Moderate
Label’s interaction-driven risk context for myopathy/rhabdomyolysis (e.g., cyclosporine and strong CYP3A4 inhibitors; grapefruit juice) is not addressed by the claims list.
Importance:
Moderate
Label’s skeletal muscle warning framework (myopathy/rhabdomyolysis) is only partially reflected; the excerpt does not include the detailed patient 'red flag' language claimed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some muscle-risk statements are directionally consistent (myalgia; rare rhabdomyolysis). However, several specific symptom red-flag and activity/timing statements are not supported by the provided label excerpt, and key labeled contraindication/interaction information is omitted from the claims list, reducing labeling alignment for safe and accurate communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims introduce non-labeled specificity about flexibility/range-of-motion and activity-based timing/red-flag symptom descriptions that are not supported by the provided Lipitor prescribing information excerpt.
Suggested Improvement
Restrict claims to labeled muscle adverse reactions (e.g., myalgia) and labeled skeletal muscle warning content (rare rhabdomyolysis/myopathy risk; interaction/dose-related risk context) using the language present in the label excerpt. Avoid unsupported yoga/stretching/flexibility explanations and unsupported 'red flag' symptom descriptions unless directly supported by the label text provided.